Novo Nordisk H-1B Visa Sponsorship 2026
Pharma & biotech · H-1B sponsor · FY2017–2026
🏢 Plainsboro, NJ HQ🌐 novonordisk.com
Does Novo Nordisk sponsor H-1B visas and green cards?
Yes. Novo Nordisk has filed 262 H-1B LCAs and 39 PERM green-card cases with the U.S. Department of Labor between FY2017 and FY2026. In FY2025–2026 Novo Nordisk filed 104 H-1B LCAs at a median base salary of $137,878, about 13% above the national H-1B median of $121,966 for the same period, and 13 green-card cases were decided.
H-1B pay & filings by year
Median base salary (line) and H-1B filing volume (bars), by fiscal year
Show the numbers behind this chart
| Fiscal year | H-1B LCA filings | Median base salary |
|---|---|---|
| FY2026 (partial) | 41 | $147k |
| FY2025 | 63 | $135k |
| FY2024 | 49 | $151k |
| FY2023 | 22 | $152k |
| FY2022 | 18 | $129k |
| FY2021 | 18 | $114k |
| FY2020 | 18 | $122k |
| FY2019 | 16 | $100k |
| FY2018 | 6 | $112k |
| FY2017 | 11 | $109k |
A fiscal year marked partial is still in progress, so its total is lower than a complete year and the two are not comparable.
H-1B wage floor & filing outcomes
What this employer pays against the DOL legal minimum, how senior the roles are, and how the filings were decided
Roles they file for
Where they hire
Green-card (PERM) pay & filings by year
Median green-card offer (line) and PERM filing volume (bars), by fiscal year †
Show the numbers behind this chart
| Fiscal year | PERM filings | Median base salary |
|---|---|---|
| FY2026 (partial) | 5 | $136k |
| FY2025 | 8 | $156k |
| FY2024 | 3 | $125k |
| FY2023 | 3 | $150k |
| FY2022 | 2 | $112k |
| FY2021 | 5 | $173k |
| FY2020 | 3 | $151k |
| FY2019 | 4 | $130k |
| FY2018 | 4 | $110k |
| FY2017 | 2 | $99k |
Green-card route and outcomes
Worker backgrounds · FY2017–2024
Where their green-card (PERM) workers studied & came from
Patents
- Granted
- 82
- US patents
- Published, not yet granted
- 1
- applications
- Most recent grant
- February 22, 2005
- Top area
- Microorganisms or enzymes; compositions thereof; propagating54
Pay against the local market
Novo Nordisk’s 10 most-filed occupations and metros, FY2019–FY2026. Its median base salary is 116% of the local BLS median for the same work.
| Occupation | Metro | Filings | Novo Nordisk pay | Local BLS median‡ | vs market |
|---|---|---|---|---|---|
| Biological Scientists, All Other | Boston, MA | 23 | $126,582 | $103,120 | 123% |
| Data Scientists | Boston, MA | 10 | $144,591 | $131,830 | 110% |
| Industrial Engineers | Raleigh, NC | 7 | $126,786 | $101,710 | 125% |
| Biochemists and Biophysicists | Boston, MA | 5 | $136,144 | $127,510 | 107% |
| Chemists | Boston, MA | 5 | $111,602 | $130,830 | 85% |
| Bioengineers and Biomedical Engineers | San Francisco, CA | 4 | $121,628 | $127,270 | 96% |
| Medical Scientists | Boston, MA | 3 | $153,294 | $129,230 | 119% |
| Chemists | Durham, NC | 2 | $105,000 | $78,240 | 134% |
| Biological Scientists, All Other | Seattle, WA | 2 | $102,449 | $83,060 | 123% |
| Biological Scientists, All Other | San Francisco, CA | 2 | $77,523 | $118,290 | 66% |
About Novo Nordisk
Novo Nordisk is a pharma & biotech company based in Bagsværd, Denmark. It was founded in 1923 and has about 69,505 employees worldwide. It is listed on NYSE as NVO.
- Name (DOL filings)
- Novo Nordisk
- Listed
- NYSE: NVO
- Sponsoring since
- FY2017 or earlier
- Headquarters
- Novo Alle Dk 2880, Bagsvaerd Denmark, G7, 00000
- Industry
- Pharma & biotech
- Employees (global)
- 69,505 (2025)
- Revenue FY2025
- DKK 309.1B +6% from DKK 290.4B
- Net income FY2025
- DKK 102.4B +1% from DKK 101.0B
- R&D FY2025
- DKK 52.0B (17% of revenue)
Spends 17% of revenue on R&D, against a 73% median across the 122 Pharmaceutical Preparations filers we hold SEC data for.
Novo Nordisk pays a median H-1B base of $132,289 across FY2017–2026, about 25% above the typical Pharma & biotech sponsor.
H-1B sponsors similar to Novo Nordisk
| Employer | Filings, all years | Recent filings | Median base | New employment | Level III-IV roles |
|---|---|---|---|---|---|
| Zoetis | 702 | 185 | $122k | 58 | 62% |
| GSK | 648 | 128 | $127k | 46 | 39% |
| Boehringer Ingelheim | 620 | 120 | $145k | 55 | 73% |
| Novo Nordisk | 262 | 104 | $138k | 42 | 63% |
| BioMarin Pharmaceutical | 261 | 42 | $133k | 11 | 42% |
| Lupin | 261 | 35 | $110k | 14 | 26% |
| BeOne Medicines | 256 | 61 | $186k | 7 | 83% |
